Isomorphic Labs, an AI drug discovery company spun out of Google DeepMind, has raised $5 billion in Series C funding.
Isomorphic Labs, an AI drug discovery company spun out of Google DeepMind, has raised $5 billion in Series C funding.
The round was co-led by Greenoaks and Sequoia Capital, with participation from Alphabet and Andreessen Horowitz. The funding will help scale its IsoDDE AI drug design platform, advance treatments for cancer and immune-related diseases, and move drug candidates toward clinical trials.